FDA approves new Alzheimer's drug, offering hope for slower cognitive decline
The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.
![FDA approves new Alzheimer's drug, offering hope for slower cognitive decline](https://i.cbc.ca/1.6764422.1677700619!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_620/eli-lilly.jpg)
![An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey in March 2021. White office building with glass windows, and a white sign with word Lilly in red cursive letters](https://i.cbc.ca/1.6764422.1677700619!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_620/eli-lilly.jpg)
The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.